[
    [
        {
            "time": "",
            "original_text": "华润双鹤销售费18亿是研发7倍 业绩不够竟然收购来凑",
            "features": {
                "keywords": [
                    "华润双鹤",
                    "销售费",
                    "研发",
                    "收购"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华润双鹤销售费18亿是研发7倍 业绩不够竟然收购来凑",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药板块“半月惊魂”！股民惨遭“闷杀”后该怎么办？",
            "features": {
                "keywords": [
                    "医药板块",
                    "半月惊魂",
                    "闷杀"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药板块“半月惊魂”！股民惨遭“闷杀”后该怎么办？",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "320亿资金争夺20股：主力资金重点出击4股(名单)",
            "features": {
                "keywords": [
                    "资金争夺",
                    "主力资金",
                    "出击",
                    "名单"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "320亿资金争夺20股：主力资金重点出击4股(名单)",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "美国药企高研发中国药企重销售，为何中国药企还能高盈利",
            "features": {
                "keywords": [
                    "美国药企",
                    "研发",
                    "中国药企",
                    "销售",
                    "高盈利"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "美国药企高研发中国药企重销售，为何中国药企还能高盈利",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[强于大市评级]医药生物行业研究周报：优选中报业绩优异标的 布局估值切换行情",
            "features": {
                "keywords": [
                    "强于大市",
                    "医药生物",
                    "中报业绩",
                    "估值切换"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[强于大市评级]医药生物行业研究周报：优选中报业绩优异标的 布局估值切换行情",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]